Drug intelligence / Profile preview

NMJ-3

Development stage: Preclinical
Lead developer: Manipal Academy of Higher Education
Modality: Small Molecules
Administration: Intravenous, Intramuscular

Overview

NMJ-3 is a novel small molecule histone deacetylase (HDAC) inhibitor, specifically characterized as a cinnamyl sulfonamide-hydroxamic acid derivative. It has demonstrated neuroprotective, anti-inflammatory, and antioxidant properties in preclinical models of neurodegenerative disorders. In studies involving MPTP-induced Parkinson's disease and Aβ-induced Alzheimer's disease models, NMJ-3 has been shown to inhibit oxidative stress, reduce neuroinflammation, and restore dopamine levels in the striatum. By modulating epigenetic pathways through HDAC inhibition, it protects neuronal cells from degeneration and improves locomotor and cognitive deficits in animal models.

Other names: cinnamyl sulfonamide-hydroxamic acid derivative

Targets

HDAC (HDAC family)

Beyond the preview

Go deeper on NMJ-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NMJ-3.

Explore the full profile